Clinical Trials

Clearside Biomedical is currently evaluating Zuprata™, our proprietary, preservative-free formulation of the corticosteroid triamcinolone acetonide, in clinical trials for the treatment of Uveitis and Retinal Vein Occlusion.  For more information about our clinical trial programs, please click on the appropriate link below -

Uveitis

A Randomized, Masked, Multi-Center Controlled Clinical Trial to Study the Safety and Efficacy of Zuprata, Triamcinolone Acetonide Injectable Suspension in the Treatment of Subjects With Macular Edema Associated With Non-Infectious Uveitis (PEACHTREE) – Ongoing, Recruiting Patients

  • PURPOSE – This study is to evaluate the safety and efficacy of suprachoroidally administered Zuprata, triamcinolone acetonide injectable suspension, in subjects with macular edema associated with non-infectious uveitis. Qualified subjects will be randomized to receive two unilateral suprachoroidal injections of Zuprata administered to the study eye or two unilateral sham injection procedures administered to the study eye approximately 12 weeks apart.
  • https://clinicaltrials.gov/ct2/show/NCT02595398?term=clearside+biomedical&rank=4

A Randomized, Masked, Multi-Center Study to Assess the Safety and Efficacy of Zuprata, Triamcinolone Acetonide Suspension in the Treatment of Subjects With Macular Edema Following Uveitis (DOGWOOD) – COMPLETED

  • PURPOSE – This study is designed to evaluate the safety and efficacy of triamcinolone acetonide, Zuprata, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of Zuprata will each be evaluated in subjects with macular edema following non-infectious uveitis.
  • https://clinicaltrials.gov/ct2/show/NCT02255032?term=clearside+biomedical&rank=2

Open Label, Safety and Tolerability Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle in Subjects With Non-Infectious Uveitis – COMPLETED

 

Retinal Vein Occlusion (RVO)

Safety and Efficacy of Suprachoroidal Zuprata in Combination With Intravitreal Aflibercept in Subjects With Macular Edema Following Retinal Vein Occlusion (TANZANITE) – COMPLETED